Clinical Trial Update: A Study of JNJ-64619178, an Inhibitor of PRMT5 in Participants With Advanced Solid Tumors, NHL, and Lower Risk MDS [Phase 1]

View source ↗

Summary

Phase 1 study of JNJ-64619178, a PRMT5 inhibitor, in participants with advanced solid tumors, Non-Hodgkin Lymphoma, and lower-risk myelodysplastic syndromes has…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Myelodysplastic Syndromes
• Non-hodgkin Lymphoma
• Solid Tumors

Drugs mentioned

• JNJ-64619178

Snippet

Sponsor: Janssen Research & Development, LLC | Conditions: Neoplasms, Solid Tumor, Adult | Phase 1 | Status: COMPLETED